IL316357A - Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies - Google Patents
Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesInfo
- Publication number
- IL316357A IL316357A IL316357A IL31635724A IL316357A IL 316357 A IL316357 A IL 316357A IL 316357 A IL316357 A IL 316357A IL 31635724 A IL31635724 A IL 31635724A IL 316357 A IL316357 A IL 316357A
- Authority
- IL
- Israel
- Prior art keywords
- sequence
- seq
- aspects
- cdr
- antibody comprises
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539527P | 2017-07-31 | 2017-07-31 | |
| PCT/US2018/044449 WO2019027935A1 (en) | 2017-07-31 | 2018-07-30 | ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316357A true IL316357A (en) | 2024-12-01 |
Family
ID=65233024
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316357A IL316357A (en) | 2017-07-31 | 2018-07-30 | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| IL272367A IL272367B2 (en) | 2017-07-31 | 2018-07-30 | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272367A IL272367B2 (en) | 2017-07-31 | 2018-07-30 | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US11345757B2 (https=) |
| EP (1) | EP3661966A4 (https=) |
| JP (4) | JP7113071B2 (https=) |
| KR (2) | KR20240153413A (https=) |
| CN (2) | CN118978594A (https=) |
| AR (1) | AR112639A1 (https=) |
| AU (1) | AU2018312251B2 (https=) |
| BR (1) | BR112020002012A8 (https=) |
| CA (1) | CA3071540A1 (https=) |
| CL (1) | CL2020000281A1 (https=) |
| CO (1) | CO2020001983A2 (https=) |
| CR (1) | CR20200101A (https=) |
| DO (1) | DOP2020000021A (https=) |
| IL (2) | IL316357A (https=) |
| MX (1) | MX2020001270A (https=) |
| MY (1) | MY202018A (https=) |
| PE (1) | PE20200617A1 (https=) |
| PH (1) | PH12020500240A1 (https=) |
| SG (2) | SG10202111869SA (https=) |
| TW (2) | TW202344516A (https=) |
| WO (1) | WO2019027935A1 (https=) |
| ZA (1) | ZA202000608B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| MY202018A (en) | 2017-07-31 | 2024-03-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230020023A (ko) * | 2018-03-14 | 2023-02-09 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
| EP3788079A4 (en) | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| DK3807316T3 (da) | 2018-06-18 | 2024-07-29 | Innate Pharma | Sammensætninger og fremgangsmåder til behandling af cancer |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US20230242660A1 (en) * | 2019-02-21 | 2023-08-03 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CA3149494A1 (en) * | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
| JP7727387B2 (ja) | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
| KR20220062500A (ko) * | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| KR20230019414A (ko) * | 2020-04-03 | 2023-02-08 | 트리슐라 테라퓨틱스, 인코포레이티드 | 항-cd39 항체 및 입양 세포 요법을 포함하는 조합 요법 |
| CA3187944A1 (en) | 2020-06-22 | 2021-12-30 | Ngm Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| WO2021260966A1 (ja) * | 2020-06-25 | 2021-12-30 | 学校法人埼玉医科大学 | アデノシン産生酵素を標的とする組成物 |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| AU2021389989A1 (en) * | 2020-11-27 | 2023-06-08 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfβeta |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CN118715243A (zh) * | 2022-01-24 | 2024-09-27 | 上海华奥泰生物药业股份有限公司 | Cd39抗原结合蛋白及其应用 |
| MX2024010646A (es) | 2022-03-03 | 2024-09-19 | Arcus Biosciences Inc | Anticuerpos anti-cd39 y uso de los mismos. |
| WO2023164872A1 (en) * | 2022-03-03 | 2023-09-07 | Arcus Biosciences, Inc. | Anti-cd39 antibodies and use thereof |
| US20250188165A1 (en) * | 2022-03-04 | 2025-06-12 | Trishula Therapeutics Inc | Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer |
| US20250215105A1 (en) * | 2022-03-25 | 2025-07-03 | Brightpath Biotherapeutics Co., Ltd. | Anti-cd39 antibody |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2024030956A2 (en) * | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| EP4669350A1 (en) * | 2023-02-24 | 2025-12-31 | Institut National de la Santé et de la Recherche Médicale | ENDOMETRIOSIS TREATMENT METHODS |
| CN116589584B (zh) * | 2023-05-24 | 2025-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| KR102879536B1 (ko) * | 2023-06-09 | 2025-10-31 | 주식회사 브이티 | 시카 추출물이 함침된 마이크로 니들을 유효성분으로 포함하는 화장료 조성물 및 이의 제조방법 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN119798442B (zh) * | 2023-12-27 | 2025-12-16 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
| WO2026039538A1 (en) * | 2024-08-14 | 2026-02-19 | Trishula Therapeutics, Inc. | Methods of treating pancreatic tumors expressing certain biomarkers |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186745T1 (de) | 1995-01-18 | 1999-12-15 | Roche Diagnostics Gmbh | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern |
| WO1996032471A2 (en) | 1995-04-10 | 1996-10-17 | Universite De Sherbrooke | Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology |
| US6447771B1 (en) | 1999-03-19 | 2002-09-10 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| US6476211B1 (en) | 1998-07-16 | 2002-11-05 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
| EP1133563A2 (en) | 1998-07-16 | 2001-09-19 | Hyseq, Inc. | Methods and molecules relating to cd39-like polypeptides |
| US6387645B1 (en) | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| US6780977B1 (en) | 1999-01-29 | 2004-08-24 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6899875B1 (en) | 1999-01-29 | 2005-05-31 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6350447B1 (en) | 1999-01-29 | 2002-02-26 | Hyseq, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6335013B1 (en) | 1999-03-19 | 2002-01-01 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
| WO2003052121A2 (en) | 2001-12-17 | 2003-06-26 | Beth Israel Deaconess Medical Center | Method of reducing angiogenesis |
| US20050037382A1 (en) | 2003-04-08 | 2005-02-17 | Robson Simon C. | Methods and compositions for treating and preventing autoimmune disorders |
| WO2006111986A1 (en) | 2005-04-19 | 2006-10-26 | Fondazione Santa Lucia I.R.C.C.S. | Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof |
| CA2696263C (en) * | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
| US20110020329A1 (en) * | 2007-11-30 | 2011-01-27 | Bristol-Myers Squibb Company | Conjugates of anti-rg-1 antibodies |
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| EP2654789B1 (en) | 2010-12-22 | 2018-05-30 | Orega Biotech | Antibodies against human cd39 and use thereof |
| US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
| MA39819A (fr) * | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| EP3215538A4 (en) | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2016191703A2 (en) | 2015-05-27 | 2016-12-01 | The Trustees Of Columbia University In The City Of New York | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer |
| PT3356413T (pt) * | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CA3005986A1 (en) | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| EP3912681A1 (en) | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| EP3744348B1 (en) | 2016-05-06 | 2022-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| KR102638592B1 (ko) | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| MY202018A (en) | 2017-07-31 | 2024-03-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| BR112020006809A2 (pt) | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| KR102781619B1 (ko) | 2017-11-15 | 2025-03-14 | 이나뜨 파르마 에스.에이. | 암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체 |
| KR20230020023A (ko) | 2018-03-14 | 2023-02-09 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
| CA3149494A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
| JP7727387B2 (ja) | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
-
2018
- 2018-07-30 MY MYPI2020000520A patent/MY202018A/en unknown
- 2018-07-30 SG SG10202111869SA patent/SG10202111869SA/en unknown
- 2018-07-30 CN CN202410622919.8A patent/CN118978594A/zh active Pending
- 2018-07-30 WO PCT/US2018/044449 patent/WO2019027935A1/en not_active Ceased
- 2018-07-30 CR CR20200101A patent/CR20200101A/es unknown
- 2018-07-30 IL IL316357A patent/IL316357A/en unknown
- 2018-07-30 IL IL272367A patent/IL272367B2/en unknown
- 2018-07-30 EP EP18841649.9A patent/EP3661966A4/en active Pending
- 2018-07-30 KR KR1020247034153A patent/KR20240153413A/ko active Pending
- 2018-07-30 CN CN201880064027.3A patent/CN111448211B/zh active Active
- 2018-07-30 CA CA3071540A patent/CA3071540A1/en active Pending
- 2018-07-30 BR BR112020002012A patent/BR112020002012A8/pt unknown
- 2018-07-30 SG SG11202000820PA patent/SG11202000820PA/en unknown
- 2018-07-30 KR KR1020207005353A patent/KR102718932B1/ko active Active
- 2018-07-30 PE PE2020000166A patent/PE20200617A1/es unknown
- 2018-07-30 JP JP2020506222A patent/JP7113071B2/ja active Active
- 2018-07-30 AU AU2018312251A patent/AU2018312251B2/en active Active
- 2018-07-30 US US16/635,526 patent/US11345757B2/en active Active
- 2018-07-30 MX MX2020001270A patent/MX2020001270A/es unknown
- 2018-07-30 US US16/049,736 patent/US20190062448A1/en not_active Abandoned
- 2018-07-31 TW TW112113090A patent/TW202344516A/zh unknown
- 2018-07-31 TW TW107126546A patent/TWI798242B/zh active
- 2018-07-31 AR ARP180102152 patent/AR112639A1/es unknown
-
2020
- 2020-01-29 ZA ZA2020/00608A patent/ZA202000608B/en unknown
- 2020-01-31 CL CL2020000281A patent/CL2020000281A1/es unknown
- 2020-01-31 PH PH12020500240A patent/PH12020500240A1/en unknown
- 2020-01-31 DO DO2020000021A patent/DOP2020000021A/es unknown
- 2020-02-25 CO CONC2020/0001983A patent/CO2020001983A2/es unknown
-
2021
- 2021-09-07 US US17/468,366 patent/US20210403593A1/en not_active Abandoned
-
2022
- 2022-04-20 US US17/725,142 patent/US20220340680A1/en not_active Abandoned
- 2022-05-30 US US17/827,989 patent/US20220372163A1/en not_active Abandoned
- 2022-07-25 JP JP2022118008A patent/JP2022145720A/ja not_active Withdrawn
-
2024
- 2024-03-28 JP JP2024053368A patent/JP7690085B2/ja active Active
- 2024-09-24 US US18/895,094 patent/US20250026850A1/en active Pending
-
2025
- 2025-05-28 JP JP2025088950A patent/JP2025116106A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690085B2 (ja) | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 | |
| US20250353913A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| EP3558365B1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| RU2795348C2 (ru) | Анти-cd39 антитела, композиции, содержащие анти-cd39 антитела, и способы применения анти-cd39 антител | |
| WO2025054320A1 (en) | Anti-ackr4 antibodies, compositions and uses thereof | |
| EA045983B1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| EA045991B1 (ru) | Антигенсвязывающие белки против нейропилина и способы их применения |